OBJECTIVE: To refine the criteria for the diagnosis of amiodarone-related optic neuropathy by including a broader spectrum of clinical features, thus helping to differentiate this entity from nonarteritic anterior ischemic optic neuropathy coincidentally affecting a patient taking amiodarone. METHODS: A retrospective case review of 22 patients who developed optic neuropathy while taking amiodarone, in whom other systemic causes were excluded. RESULTS: We identified 3 groups of patients: those in whom a diagnosis of amiodarone-induced optic neuropathy seems probable (n = 14), those in whom an association with amiodarone optic neuropathy is indeterminate (n = 5), and those in whom the occurrence of nonarteritic anterior ischemic optic neuropathy seems to be coincidental (ie, unrelated to amiodarone) (n = 3). We formulated specific diagnostic criteria for each of these categories. CONCLUSIONS: We recommend a systematic approach that includes assessment of bilaterality, mode of onset, degree of optic nerve dysfunction, structure of the uninvolved optic disc in unilateral cases, and systemic toxic effects. Such well-defined diagnostic criteria can help the clinician in the treatment of patients with this disorder.
OBJECTIVE: To refine the criteria for the diagnosis of amiodarone-related optic neuropathy by including a broader spectrum of clinical features, thus helping to differentiate this entity from nonarteritic anterior ischemic optic neuropathy coincidentally affecting a patient taking amiodarone. METHODS: A retrospective case review of 22 patients who developed optic neuropathy while taking amiodarone, in whom other systemic causes were excluded. RESULTS: We identified 3 groups of patients: those in whom a diagnosis of amiodarone-induced optic neuropathy seems probable (n = 14), those in whom an association with amiodaroneoptic neuropathy is indeterminate (n = 5), and those in whom the occurrence of nonarteritic anterior ischemic optic neuropathy seems to be coincidental (ie, unrelated to amiodarone) (n = 3). We formulated specific diagnostic criteria for each of these categories. CONCLUSIONS: We recommend a systematic approach that includes assessment of bilaterality, mode of onset, degree of optic nerve dysfunction, structure of the uninvolved optic disc in unilateral cases, and systemic toxic effects. Such well-defined diagnostic criteria can help the clinician in the treatment of patients with this disorder.
Authors: Med Alejandro Martínez-LóPez-Portillo; Bertha O Martínez-Gamero; Jibran Mohamed-Noriega; Med Humberto Cavazos-Adame; Med Jesús Mohamed-Hamsho Journal: J Clin Diagn Res Date: 2014-04-15
Authors: Rod S Passman; Charles L Bennett; Joseph M Purpura; Rashmi Kapur; Lenworth N Johnson; Dennis W Raisch; Dennis P West; Beatrice J Edwards; Steven M Belknap; Dustin B Liebling; Mathew J Fisher; Athena T Samaras; Lisa-Gaye A Jones; Katrina-Marie E Tulas; June M McKoy Journal: Am J Med Date: 2012-03-03 Impact factor: 4.965
Authors: Evelyn C O'Neill; Helen V Danesh-Meyer; Paul P Connell; Ian A Trounce; Michael A Coote; David A Mackey; Jonathan G Crowston Journal: Nat Rev Neurol Date: 2010-03-09 Impact factor: 42.937
Authors: Joel S Mindel; Jill Anderson; Anne Hellkamp; George Johnson; Jeanne E Poole; Daniel B Mark; Kerry L Lee; Gust H Bardy Journal: Am Heart J Date: 2007-05 Impact factor: 4.749